Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double attack: surgery plus laser zaps deadly brain tumors

NCT ID NCT07384884

Disease control Sponsor: King's College Hospital NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study tests a new approach for a rare and aggressive brain tumor called butterfly glioblastoma, which crosses both sides of the brain and has a very poor outlook. The treatment combines open surgery to remove as much tumor as possible from one side, followed by a minimally invasive laser therapy to destroy the remaining tumor on the other side. The goal is to improve survival and preserve brain function, with 12 participants being closely monitored for cognitive and quality-of-life outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
surgery and laser interstitial thermal therapy (LITT)
What this could lead to
If successful, this combined approach could offer a new treatment option for patients with butterfly glioblastoma, potentially extending survival and reducing brain damage compared to current methods.
What could go wrong
This is a very early, small trial with only 12 participants, so results may not apply to all patients. The procedure carries risks like infection, bleeding, or stroke, and the tumor may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Presumptive diagnosis of bGBM as per preoperative MRI and MDT assessment 2. Presumed residual / smaller component of the bGBM has to be \< 2.5cm 3. Performance Status 0-1 4. Able to consent for the study Exclusion Criteria: 1. bGBM measuring \>2.5 cm in both hemispheres. 2. Tumour progression between surgical debulking and LITT treatment 3. Severe complications after surgery (hydrocephalus, infection, heamatoma, stroke)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumours are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumours GBM

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King's College NHS Foundation Trust

    RECRUITING

    London, SE5 9RS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.